[Vaccine for the prevention of herpes zoster and postherpetic neuralgia in adults]
Ruiz Aragon J, Villegas Portero R
Record ID 32011000626
Spanish
Authors' recommendations:
The reactivation of the Varicela-Zoster virus in adults produces an eruption known as herpes-zoster (HZ) that can give rise to serious complications, such as encephalitis or postherpetic neuralgia (PHN).The fact that this pathology mainly affects older people is why the objective of the development of a vaccine would be to diminish the incidence of the infection and the associated pain mainly in people older than 60 years of age.Few works have been located that assess the effectiveness, safety and costeffectiveness of this vaccine. The quality of the analysed clinical trials was high.They are safe vaccines that present few adverse effects, and in the analysed trials, the adverse reactions that did take place, occurred indiscriminately in both the vaccinated group and the placebo group; there have been occasional severe adverse effects.There is an attenuated virus vaccine (strain OKA/Merck) that has recently been approved (6/06/06) and marketed in Spain under the name Zostavax® from Merck laboratories.The vaccine has demonstrated effectiveness in the reduction of the incidence of HZ and PHN, as well as in the reduction of the duration and severity of their associated pain.The vaccine is contraindicated in immunodepressed patients and those allergic to its components.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
https://www.aetsa.org/download/publicaciones/antiguas/AETSA_2007-02-6_Vacuna_Zoster.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Herpes Zoster
- Neuralgia, Postherpetic
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.